We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Shimadzu Medical Systems

Manufactures analytical instruments, testing and measuring instruments and diagnostic imaging systems read more Featured Products: More products

Download Mobile App




Groundbreaking AI-Powered UV-C Disinfection Technology Redefines Infection Control Landscape

By HospiMedica International staff writers
Posted on 27 Jun 2023

Healthcare-associated infection (HCAI) is a widespread complication in healthcare management, posing a significant health risk due to its potential to increase patient morbidity and mortality, prolong hospital stays, and escalate associated costs. More...

The emergence of serious infections like Severe Acute Respiratory Syndrome (SARS) and reemerging diseases such as plague and tuberculosis has underscored the need for effective infection control across all healthcare environments. Now, an innovative artificial intelligence (AI)-enhanced UV-C disinfection technology aims to redefine the landscape of infection control.

A strategic partnership between Shimadzu Corporation (Kyoto, Japan) and Shyld (Sunnyvale, CA, USA) has resulted in the entry of the cutting-edge Shyld AI disinfection technology in the hospital infection control market. This innovation automatically detects risks in real-time and kills pathogens on various surfaces using UV-C light. Shyld AI incorporates advanced AI and optics to revolutionize indoor air and surface disinfection, safeguarding patients as well as staff. This avant-garde technology underscores the increasing role of AI in refining healthcare processes, minimizing operational costs, and addressing ongoing staff shortages.

The AI-enabled UV-C disinfection technology designed for hospitals and healthcare facilities automatically detects and assesses risks in real time. It initiates the disinfection of frequently touched surfaces immediately after a room is vacated and identifies human presence in real-time to mitigate risks. The targeted and directional disinfection considerably cuts down the time required for room disinfection, and its round-the-clock hygiene monitoring ensures no potential risk is overlooked. By eliminating germs before they can spread, the Shyld AI disinfection technology reduces the incidence of Hospital-Acquired Infections (HAI), patient readmissions, and disease transmission.

Moreover, Shyld’s intuitive and comprehensive infection monitoring tools take infection prevention to the next level. A single dashboard provides unlimited insights, enabling users to view and track all infection and disinfection reports across the organization in one location. Users can select any report for a detailed analysis of each device, building, floor, and room over time. The technology also permits users to customize their UV disinfection zones and specify unlimited stop zones within each room to protect samples or equipment from UV exposure. It allows for the creation of individual UV disinfection zones within each room, limiting the disinfection area to the desired sections.

"This new AI-powered, automatic UV-C disinfection solution is a testament to the transformative potential of artificial intelligence in revolutionizing healthcare protocols," said Hiroto Itoi, CTO of Shimadzu Corporation. "As global emphasis on health and safety escalates, our alliance with Shyld emboldens us to rewrite the narrative around disinfection protocols. By harmonizing our cutting-edge optical technology with Shyld's sophisticated AI, we're poised to roll out a game-changing UV-C disinfection solution, epitomizing Shimadzu's dedication to bolstering human health through innovative strides."

"This partnership stands as a hallmark of Shyld's mission to catalyze industrial transformation through AI. By synergizing our AI expertise with Shimadzu's optical prowess, we are not merely engineering a product but trailblazing towards a safer, healthier future," added Mohammad Noshad, CEO of Shyld.

Related Links:
Shimadzu Corporation
Shyld


Gold Member
Blood Gas Analyzer
i-Check200
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Medical-Grade Display
HL2316SHTB
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Credit: MedUni Wien/Houdek

New Surgical Technique Enlarges Aortic Root for Larger Valve Implantation

When replacing a diseased aortic valve, a small aortic root can prevent surgeons from implanting a prosthesis large enough for the patient’s body size. This can lead to patient-prosthesis mismatch, causing... Read more

Medical Imaging

view channel
Image: The tool analyzes 3D time-of-flight MR angiography to measure brain vessel length, radius, volume, branching, tortuosity, and other structural features. (Photo courtesy of University of Rochester Medical Center)

MRI Tool Analysis Identifies Vascular Differences in Cerebral Small Vessel Disease

Cerebral small vessel disease (CSVD) involves changes or damage to the brain’s small blood vessels and is associated with stroke and cognitive impairment. Magnetic resonance imaging (MRI) can show cerebral... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.